Mitigating Brain MR Imaging Degradation Due to Ferumoxytol Therapy in Patients with Iron Deficiency Anemia

Seunghong Rhee1, An M Tran1, Thomas J O'Neill2

  • 1From the Department of Radiology, Texas Tech University Health Sciences Center El Paso, El Paso, Texas.

Insights

Ferumoxytol, used for anemia, can affect brain MRI scans. Waiting 5-6 days after treatment before magnetic resonance imaging (MRI) minimizes these unintended enhancement and artifact effects.

Area of Science:

  • Radiology
  • Neuroradiology
  • Iron Metabolism

Background:

  • Ferumoxytol is an FDA-approved iron deficiency anemia treatment.
  • It is commonly used off-label as a magnetic resonance imaging (MRI) contrast agent.
  • Unintended effects on brain MRI post-treatment, especially on susceptibility weighted imaging (SWI) and gradient recalled echo (GRE) sequences, require further investigation.

Purpose of the Study:

  • To determine the optimal time interval between ferumoxytol administration and brain MRI.
  • To minimize unintended enhancement and signal loss artifacts in MRI following ferumoxytol treatment.

Main Methods:

  • Retrospective analysis of 40 patients who received brain MRI within 3 months of ferumoxytol treatment.
  • Evaluation of MRI sequences including T1 weighted, SWI, and GRE for enhancement and artifacts.
  • Correlation of MRI findings with the time interval since ferumoxytol administration.

Main Results:

  • 68% of patients showed enhancement or signal drop on T1 weighted images.
  • 63% exhibited susceptibility artifacts on SWI/GRE sequences.
  • These effects were observed within 3 months of ferumoxytol administration.

Conclusions:

  • A 5-6 day interval between ferumoxytol administration and brain MRI is recommended.
  • This interval helps reduce unintended enhancement and susceptibility artifacts.
  • Optimizing MRI timing improves diagnostic accuracy after ferumoxytol therapy.